Compare
Protagonist Therapeutics, Inc vs Septerna, Inc. vs Cumberland Pharmaceuticals Inc vs Xilio Therapeutics, Inc.
| Latest fiscal year | Protagonist Therapeutics, Inc PTGX | Septerna, Inc. SEPN | Cumberland Pharmaceuticals Inc CPIX | Xilio Therapeutics, Inc. XLO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $46.02M | $45.95M | $44.52M | $43.77M |
| Revenue growth (YoY) | -89.4% | n/m | +17.6% | +589.9% |
| Gross margin | n/a | n/a | 85.0% (computed) | n/a |
| Operating margin | -343.6% | -148.6% | -6.3% | -95.9% |
| Net margin | -282.8% | -106.4% | -6.4% | -80.1% |
| Net income | -$130.15M | -$48.88M | -$2.84M | -$35.04M |
| EPS (Diluted) | -$2.05 | -$1.10 | -$0.19 | -$4.19 |
| Operating cash flow | $57.67M | $110.19M | $4.93M | -$4.99M |
| Free cash flow | $56.08M | $109.67M | $4.83M | -$5.51M |
| Cash & equivalents | $128.39M | $120.72M | $11.44M | $137.53M |
| Total assets | $668.19M | $596.19M | $76.82M | $154.69M |
| Total liabilities | $53.48M | $214.26M | $52.28M | $119.41M |
| Shareholders' equity | $614.71M | $381.93M | $24.88M | $35.27M |
| Return on year-end equity | -21.2% | -12.8% | -11.4% | -99.3% |
| Shares outstanding | 62.58M | 44.81M | 14.96M | 4.53M |
Revenue, most recent five fiscal years
| Fiscal year | Protagonist Therapeutics, Inc | Septerna, Inc. | Cumberland Pharmaceuticals Inc | Xilio Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $46.02M Ended 2025-12-31 | $45.95M Ended 2025-12-31 | $44.52M Ended 2025-12-31 | $43.77M Ended 2025-12-31 |
| 1 year earlier | $434.43M Ended 2024-12-31 | $1.07M Ended 2024-12-31 | $37.87M Ended 2024-12-31 | $6.34M Ended 2024-12-31 |
| 2 years earlier | $60.00M Ended 2023-12-31 | $151.0K Ended 2023-12-31 | $39.55M Ended 2023-12-31 | n/a |
| 3 years earlier | $26.58M Ended 2022-12-31 | n/a | $42.01M Ended 2022-12-31 | n/a |
| 4 years earlier | $27.36M Ended 2021-12-31 | n/a | $35.05M Ended 2021-12-31 | n/a |